The FDA on Thursday raised fresh quality concerns about Emergent BioSolutions’ manufacturing site in Baltimore, which has more recently been taken over by J&J after an error caused the site to discard about 15 million doses of the company’s vaccine last month.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,